Flying The Web For News.
  • Epiphany
    Epiphany
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Rare Disease Diagnostics Emerging Technologies and Developments Report - Shift Towards a Multi-omics Approach, Collaboration Between Rare Disease Diagnostics and Pharma Companies

Details
Category: Globe NewsWire News Distribution Service

Dublin, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The "Rare Disease Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The Rare Disease Diagnostics Market was valued at USD 21.6 Billion in 2024, and is expected to reach USD 34.7 Billion by 2029, rising at a CAGR of 9.9%.


Posted: 2024-12-16 17:04:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

rare | disease | diagnostics | press | release


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Rare Disease Diagnostics Emerging Technologies and Developments Report - Shift Towards a Multi-omics Approach, Collaboration Between Rare Disease Diagnostics and Pharma Companies - Newscast

Retinitis pigmentosa therapy receives rare pediatric disease designation

Thu, 09 Jan 2025 06:19:00 GMT The FDA granted rare pediatric disease designation to VG901 for the treatment of retinitis pigmentosa caused by mutations in the CNGA1 gene, according to a press release from ViGeneron.

FDA grants rare paediatric disease designation for retinitis pigmentosa gene therapy candidate VG901 from ViGeneron

Thu, 09 Jan 2025 05:43:00 GMT ViGeneron GmbH, a clinical-stage gene therapy company based in Munich, Germany, shared details of two new milestones in an ongoing clinical trial of its therapeutic candidate VG901 ( NCT06291935 ). In ...

Rare Disease R&D: one step forward, but a long road ahead

Mon, 06 Jan 2025 16:00:00 GMT As a result, even the most basic tasks, such as correctly identifying such a disease, can be made extremely difficult. Many rare diseases require a specialist to accurately make the diagnosis ...

Immedica to buy rare disease drugmaker Marinus for $151 million

Mon, 30 Dec 2024 16:13:00 GMT The Swedish rare disease company, which opened North American headquarters in Chicago earlier this year, will pick up an FDA-approved seizure drug in the deal.

Diving Deeper In Rare Disease Research: Protheragen Unveils Diagnostic Development Services

Wed, 25 Dec 2024 16:13:00 GMT (MENAFN- ForPressRelease) Protheragen, a dedicated preclinical research Service Provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at ...


Blow Us A Whistle